MGMT and melanoma: In addition, a significant association between longer survival times, following locoregional melphalan chemotherapy in stage IIID melanoma patients with locoregional pelvic metastases, and a 14% cut-off value for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been reported [36].